Key points from article :
Forward Therapeutics is developing next-generation small molecule therapies for immunological and inflammatory disorders.
Raised $50 million in a Series A financing round.
Curie.Bio, a new biotech venture capital model, is partnering with Forward.
Curie.Bio aims to help companies increase the likelihood of developing successful medicines.
Forward's programs target key immunology nodes, aiming to reduce inflammation, promote healing and restore quality of life.
Forward's goal is to expand global patient access to high quality medicines.
